Description:
North Central Cancer Treatment Group Arms A and D Only Recurrent Research Tissue Submission Form NCT00079274 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8BC1F4CF-E66A-E266-E040-BB89AD436B4E
Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8BC1F4CF-E66A-E266-E040-BB89AD436B4EKeywords:
Versions (4)
- 8/27/12 8/27/12 -
- 1/9/15 1/9/15 - Martin Dugas
- 6/8/15 6/8/15 -
- 9/20/21 9/20/21 -
Uploaded on:
September 20, 2021
DOI:
To request one please log in.License :
Creative Commons BY-NC 3.0 LegacyModel comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
North Central Cancer Treatment Group Arms A & D Only Recurrent Research Tissue Submission Form NCT00079274
INSTRUCTIONS: Required for all Arm A and D patients having had a surgical resection for recurrent disease per Addendum 12. Submit this form <= 30 days following surgical resection following disease progression or <= 30 days following activation of Addendum 12 (dependent on IRB approval) if patient has already had disease recurrence and surgical resection to:
- StudyEvent: North Central Cancer Treatment Group Arms A & D Only Recurrent Research Tissue Submission Form